Could a platelet-boosting drug improve blood counts in certain blood cancers?
NCT ID NCT06630221
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether eltrombopag, a drug already approved for other blood disorders, can improve blood cell counts in people with low-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) who have a mutation in the TET2 gene. Participants take eltrombopag daily for up to 15 cycles. The study measures how well the drug restores healthy blood counts and tracks changes in the TET2 mutation over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- eltrombopag (Promacta)
- What this could lead to
- If it works, this could offer a new treatment option for people with low-risk MDS or CMML who have TET2 mutations, potentially improving blood counts and delaying disease progression.
- What could go wrong
- This is a small, early-phase trial with only 25 participants, so results may not apply to everyone. Eltrombopag is not yet approved for this use, and side effects or lack of response are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute
Cleveland, Ohio, 44195, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- Can engineered immune cells outsmart Hard-to-Treat blood cancers?
- Can a Two-Drug combo tame a rare blood cancer?